Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review processes ongoing in the ...

The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...

UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...

1 The results will be presented ZUG, Switzerland, December 13, 2024--Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio ...

Artisan Partners Funds offered through Artisan Partners Distributors LLC (APDLLC), member FINRA. APDLLC is a wholly owned ...

Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...

CJRB-201', a proprietary strain of Faecalibacterium with potent its anti-inflammatory effects, has demonstrated the strongest induction of regulatory T cells (Tregs) among analyzed strains.Preclinical ...